6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
3 citations
,
November 1998 in “PubMed” 1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
February 2006 in “Inpharma Weekly” February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
March 2005 in “European Urology Supplements”
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
1 citations
,
December 2011 in “Arzneimittelforschung” The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
19 citations
,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
15 citations
,
January 2020 in “RSC advances” The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
3 citations
,
October 2024 in “Advances in Therapy” Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.